Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections

Journal of Infectious Diseases

Volumn 185, Issue 9, 2002, Pages 1213-1221

  Libraty, Daniel H ^a,c   Endy, Timothy P ^b,c,e   Houng, Huo Shu H ^b   Green, Sharone ^a   Kalayanarooj, Siripen ^d   Suntayakorn, Saroj ^c   Chansiriwongs, Wanya ^d   Vaughn, David W ^b   Nisalak, Ananda ^c   Ennis, Francis A ^a   Rothman, Alan L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Kamphaeng Phet Provincial Hospital   (Thailand)

^d QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CHILD; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIREMIA;

ANTIGENS, CD; CHILD; DENGUE HEMORRHAGIC FEVER; DNA, COMPLEMENTARY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD; VIREMIA;

EID: 0036569001     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340365     Document Type: Article

References (58)

1. The dengue viruses
2. Dengue: The risk to developed and developing countries
3. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas
4. Haematology in dengue and dengue haemorrhagic fever
5. Activation of coagulation and fibrinolysis during dengue virus infection
6. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever
7. Clinical spectrum of dengue infection
8. Early clinical and laboratory indicators of acute dengue illness
9. Dengue hemorrhagic fever: Diagnosis and management
10. A prospective study of dengue infections in Bangkok
11. Dengue hemorrhagic fever in Cuba
12. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered
13. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: A pathogenetic cascade
14. Immunopathogenesis of dengue hemorrhagic fever
15. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas
16. Dengue virus structural differences that correlate with pathogenesis
17. Histocompatibility antigens and dengue hemorrhagic fever
18. Age-related changes in microvascular permeability: A significant factor in the susceptibility of children to shock?
19. Nutritional status of children with dengue hemorrhagic fever
20. Epidemic dengue hemorrhagic fever in rural Indonesia. I. Virological and epidemiological studies
21. Viraemia in patients with naturally acquired dengue infection
22. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
23. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia
24. Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction
25. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity
26. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity
27. High levels of sTNFR p75 and TNF α in dengue-infected patients
28. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever
29. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate
30. Techniques for hemagglutination and hemagglutination-inhibition with arthropod borne viruses
31. Dengue in the early febrile phase: Viremia and antibody responses
32. Antigen capture ELISA for the identification of dengue viruses
33. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction
34. Rapid and simple method for purification of nucleic acids
35. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1,2,3 and 4, using conserved and serotype-specific 3′ non-coding sequences
36. Human dendritic cells are activated by dengue virus infection: Enhancement by gamma interferon and implications for disease pathogenesis
37. An evaluation of modified case definitions for the detection of dengue hemorrhagic fever
38. High levels of viremia in patients with hantavirus pulmonary syndrome
39. Infection of human cells by dengue virus is modulated by different cell types and viral strains
40. Replication of dengue virus type 2 in human monocyte-derived macrophages: Comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein
41. The differentiation state of monocytic cells affects their susceptibility to infection and the effects of infection by dengue virus
42. Human skin Langerhans cells are targets of dengue virus infection
43. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in dengue-infected patients
44. Profile of transforming growth factor-beta 1 in patients with dengue hemorrhagic fever
45. Activation of T lymphocytes in dengue virus infections
46. Elevated levels of IL-8 in dengue hemorrhagic fever
47. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever
48. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever
49. Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: Evidence for decreased platelet production
50. Thrombocytopenia and complement activation under recombinant TNF α/IFN γ therapy in man
51. A phase I clinical trial of recombinant human tumor necrosis factor
52. The cytokine network
53. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro
54. The soluble interleukin-2 receptor: Biology, function, and clinical application
55. + cytotoxic T-lymphocyte clones
56. Serum and liver HCV RNA levels in patients with chronic hepatitis C: Correlation with clinical and histological features
57. Toga/flaviviruses: Immunopathology